South Korea · Delayed Price · Currency is KRW Genesystem Statistics
Total Valuation
Genesystem has a market cap or net worth of KRW 35.22 billion. The enterprise value is 34.13 billion.
| Market Cap | 35.22B |
| Enterprise Value | 34.13B |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genesystem has 8.29 million shares outstanding. The number of shares has increased by 6.41% in one year.
| Current Share Class | 8.29M |
| Shares Outstanding | 8.29M |
| Shares Change (YoY) | +6.41% |
| Shares Change (QoQ) | +17.10% |
| Owned by Insiders (%) | 16.15% |
| Owned by Institutions (%) | 10.89% |
| Float | 5.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 34.87 |
| PB Ratio | 3.02 |
| P/TBV Ratio | 3.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 33.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.59, with a Debt / Equity ratio of 0.33.
| Current Ratio | 3.59 |
| Quick Ratio | 2.53 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.44 |
| Interest Coverage | -64.82 |
Financial Efficiency
Return on equity (ROE) is -86.82% and return on invested capital (ROIC) is -26.47%.
| Return on Equity (ROE) | -86.82% |
| Return on Assets (ROA) | -22.78% |
| Return on Invested Capital (ROIC) | -26.47% |
| Return on Capital Employed (ROCE) | -50.81% |
| Weighted Average Cost of Capital (WACC) | 3.78% |
| Revenue Per Employee | 18.70M |
| Profits Per Employee | -190.40M |
| Employee Count | 54 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 2.11 |
Taxes
| Income Tax | -1.17B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.88% in the last 52 weeks. The beta is -0.06, so Genesystem's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -13.88% |
| 50-Day Moving Average | 3,942.70 |
| 200-Day Moving Average | 4,659.08 |
| Relative Strength Index (RSI) | 59.28 |
| Average Volume (20 Days) | 7,954 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genesystem had revenue of KRW 1.01 billion and -10.28 billion in losses. Loss per share was -1,418.71.
| Revenue | 1.01B |
| Gross Profit | -2.01B |
| Operating Income | -7.85B |
| Pretax Income | -13.89B |
| Net Income | -10.28B |
| EBITDA | -7.28B |
| EBIT | -7.85B |
| Loss Per Share | -1,418.71 |
Balance Sheet
The company has 4.82 billion in cash and 3.89 billion in debt, with a net cash position of 932.70 million or 112.56 per share.
| Cash & Cash Equivalents | 4.82B |
| Total Debt | 3.89B |
| Net Cash | 932.70M |
| Net Cash Per Share | 112.56 |
| Equity (Book Value) | 11.65B |
| Book Value Per Share | 1,425.93 |
| Working Capital | 5.83B |
Cash Flow
In the last 12 months, operating cash flow was -8.28 billion and capital expenditures -521.75 million, giving a free cash flow of -8.81 billion.
| Operating Cash Flow | -8.28B |
| Capital Expenditures | -521.75M |
| Depreciation & Amortization | 567.86M |
| Net Borrowing | -162.86M |
| Free Cash Flow | -8.81B |
| FCF Per Share | -1,062.76 |
Margins
| Gross Margin | -198.81% |
| Operating Margin | -777.39% |
| Pretax Margin | -1,375.23% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genesystem does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.41% |
| Shareholder Yield | -6.41% |
| Earnings Yield | -29.20% |
| FCF Yield | -25.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genesystem has an Altman Z-Score of 1.84 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.84 |
| Piotroski F-Score | 4 |